Emergent BioSolutions Files 8-K for Reg FD Disclosure

Ticker: EBS · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1367644

Emergent Biosolutions Inc. 8-K Filing Summary
FieldDetail
CompanyEmergent Biosolutions Inc. (EBS)
Form Type8-K
Filed DateJan 9, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, disclosure, corporate-governance

TL;DR

**EBS just dropped an 8-K for Reg FD, likely new info hitting the market.**

AI Summary

Emergent BioSolutions Inc. filed an 8-K on January 9, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. This filing indicates that the company is providing information that was not previously public, likely related to financial or operational updates. For investors, this matters because Regulation FD aims to prevent selective disclosure, meaning all investors should now have access to the same material information, which could influence their decision to buy, sell, or hold EBS stock.

Why It Matters

This filing ensures that all investors receive important company information simultaneously, promoting fairness and transparency in the market for EBS stock.

Risk Assessment

Risk Level: low — This 8-K is a standard disclosure filing and does not inherently present new risks, but rather ensures information parity.

Analyst Insight

A smart investor would look for the specific content of the Regulation FD disclosure to understand the new information and its potential impact on EBS's valuation.

Key Numbers

  • 001-33137 — Commission File Number (identifies Emergent BioSolutions Inc. with the SEC)
  • 2024-01-09 — Date of Report (indicates when the earliest event reported in the 8-K occurred)

Key Players & Entities

  • Emergent BioSolutions Inc. (company) — the registrant filing the 8-K
  • New York Stock Exchange (company) — where Emergent BioSolutions' Common Stock is registered
  • January 9, 2024 (date) — date of the earliest event reported and filing date
  • 001-33137 (dollar_amount) — Commission File Number for Emergent BioSolutions Inc.

Forward-Looking Statements

  • The detailed content of the Regulation FD disclosure will be released shortly, providing specific financial or operational updates. (Emergent BioSolutions Inc.) — high confidence, target: 2024-01-09

FAQ

What is the purpose of Emergent BioSolutions Inc.'s 8-K filing on January 9, 2024?

The 8-K filing by Emergent BioSolutions Inc. on January 9, 2024, is for a Regulation FD Disclosure and to include Financial Statements and Exhibits, as stated in the 'ITEM INFORMATION' section.

What is the trading symbol for Emergent BioSolutions Inc. on the New York Stock Exchange?

The trading symbol for Emergent BioSolutions Inc.'s Common Stock on the New York Stock Exchange is 'EBS', as indicated under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the state of incorporation for Emergent BioSolutions Inc.?

Emergent BioSolutions Inc. is incorporated in Delaware, as specified in the filing under 'State or other jurisdiction of incorporation'.

What is the business address of Emergent BioSolutions Inc.?

The business address of Emergent BioSolutions Inc. is 400 Professional Drive, Suite 400, Gaithersburg, Maryland 20879, according to the 'BUSINESS ADDRESS' section of the filing.

Does this 8-K filing indicate that Emergent BioSolutions Inc. is an emerging growth company?

No, the filing indicates with a checkbox '☐' that Emergent BioSolutions Inc. is NOT checking the box for being an emerging growth company, meaning it is not considered one under Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Filing Stats: 497 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-01-09 08:40:06

Key Financial Figures

  • $0.001 — ich registered Common Stock, Par Value $0.001 per share EBS New York Stock Exchange

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 9, 2024, the Company issued a press release announcing that during the week of January 8, 2024, representatives of the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference. A copy of the press release is attached as Exhibit 99.1 to this current Report on Form 8-K and is incorporated by reference herein. These Company representatives will present the slides furnished as Exhibit 99.2 to this Current Report on Form 8-K, which are incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits . Exhibit No. Description 99.1 Press release issued by Emergent BioSolutions Inc. on January 9, 2024 99.2 Corporate slide deck made available on January 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: January 9, 2024 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.